CO4940450A1 - Formulaciones farmaceuticas que contienen voriconazol - Google Patents

Formulaciones farmaceuticas que contienen voriconazol

Info

Publication number
CO4940450A1
CO4940450A1 CO98035641A CO98035641A CO4940450A1 CO 4940450 A1 CO4940450 A1 CO 4940450A1 CO 98035641 A CO98035641 A CO 98035641A CO 98035641 A CO98035641 A CO 98035641A CO 4940450 A1 CO4940450 A1 CO 4940450A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical formulations
formulations containing
voriconazole
containing voriconazole
pharmaceutically acceptable
Prior art date
Application number
CO98035641A
Other languages
English (en)
Spanish (es)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940450(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CO4940450A1 publication Critical patent/CO4940450A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO98035641A 1997-06-21 1998-06-23 Formulaciones farmaceuticas que contienen voriconazol CO4940450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO4940450A1 true CO4940450A1 (es) 2000-07-24

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98035641A CO4940450A1 (es) 1997-06-21 1998-06-23 Formulaciones farmaceuticas que contienen voriconazol

Country Status (47)

Country Link
US (1) US6632803B1 (enExample)
EP (1) EP1001813B8 (enExample)
JP (2) JP2000513029A (enExample)
KR (1) KR100372988B1 (enExample)
CN (1) CN1125653C (enExample)
AP (1) AP912A (enExample)
AR (1) AR015900A1 (enExample)
AT (1) ATE238812T1 (enExample)
AU (1) AU724799B2 (enExample)
BG (1) BG64584B1 (enExample)
BR (1) BRPI9809468B8 (enExample)
CA (1) CA2295035C (enExample)
CO (1) CO4940450A1 (enExample)
CZ (1) CZ289570B6 (enExample)
DE (1) DE69814091T2 (enExample)
DK (1) DK1001813T3 (enExample)
DZ (1) DZ2523A1 (enExample)
EA (1) EA001924B1 (enExample)
EG (1) EG23910A (enExample)
ES (1) ES2195355T3 (enExample)
GB (1) GB9713149D0 (enExample)
HR (1) HRP980341B1 (enExample)
HU (1) HU228338B1 (enExample)
ID (1) ID22939A (enExample)
IL (1) IL132918A (enExample)
IS (1) IS2004B (enExample)
MA (1) MA26508A1 (enExample)
ME (1) ME00907B (enExample)
MY (1) MY118151A (enExample)
NO (1) NO313125B1 (enExample)
NZ (1) NZ501066A (enExample)
OA (1) OA11232A (enExample)
PA (1) PA8453201A1 (enExample)
PE (1) PE84899A1 (enExample)
PL (1) PL191295B1 (enExample)
PT (1) PT1001813E (enExample)
RS (1) RS49633B (enExample)
SA (1) SA98190159B1 (enExample)
SI (1) SI1001813T1 (enExample)
SK (1) SK282946B6 (enExample)
TN (1) TNSN98090A1 (enExample)
TR (1) TR199903191T2 (enExample)
TW (1) TW406023B (enExample)
UA (1) UA57083C2 (enExample)
UY (1) UY25055A1 (enExample)
WO (1) WO1998058677A1 (enExample)
ZA (1) ZA985364B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
NZ537995A (en) * 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
ZA200604579B (en) * 2003-12-08 2007-10-31 Univ Arizona Synergistic anti-cancer compositions
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
RU2472510C2 (ru) * 2008-06-06 2013-01-20 Гленмарк Фармасьютикалс Лимитед Стабильная лекарственная форма для местного применения, содержащая вориконазол
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EA201270283A1 (ru) 2009-08-19 2012-12-28 Рациофарм Гмбх Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
PL3391890T3 (pl) 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
EP2409699B1 (en) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
US20130202681A1 (en) * 2012-01-05 2013-08-08 Frederick Timothy Guilford Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
AU2013259573B2 (en) 2012-05-08 2018-02-15 Onyx Therapeutics, Inc. Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
BR112014028069A2 (pt) 2012-05-11 2017-08-08 Cipla Ltd composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
BR112015016331B1 (pt) 2013-01-11 2020-05-12 Xellia Pharmaceuticals Aps Formulação farmacêutica estabilizada e método de estabilização de uma composição compreendendo voriconazol
US20140275122A1 (en) 2013-03-14 2014-09-18 Fresenius Kabi Usa, Llc Voriconazole Formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
EP3584245A4 (en) * 2017-02-17 2020-08-26 Wuhan LL Science And Technology Development Co., Ltd. TRIAZOLE ANTIBACTERIAL DERIVATIVE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
WO2021245703A2 (en) 2020-06-06 2021-12-09 Inventia Healthcare Limited Stable liquid compositions of posaconazole
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO313125B1 (no) 2002-08-19
HUP0003323A2 (hu) 2001-06-28
MY118151A (en) 2004-09-30
SA98190159B1 (ar) 2005-12-21
DZ2523A1 (fr) 2003-02-01
EA199900937A1 (ru) 2000-08-28
WO1998058677A1 (en) 1998-12-30
CA2295035A1 (en) 1998-12-30
DE69814091D1 (de) 2003-06-05
NO995565D0 (no) 1999-11-12
AU8110498A (en) 1999-01-04
HUP0003323A3 (en) 2002-01-28
NO995565L (no) 1999-11-30
JP2002332234A (ja) 2002-11-22
BG103882A (en) 2000-07-31
EP1001813A1 (en) 2000-05-24
JP5089004B2 (ja) 2012-12-05
HRP980341A2 (en) 1999-02-28
TNSN98090A1 (fr) 2005-03-15
BR9809468B1 (pt) 2013-11-12
HRP980341B1 (en) 2001-12-31
KR20010014006A (ko) 2001-02-26
AP912A (en) 2001-12-08
KR100372988B1 (ko) 2003-02-25
SK282946B6 (sk) 2003-01-09
PT1001813E (pt) 2003-07-31
ATE238812T1 (de) 2003-05-15
UA57083C2 (uk) 2003-06-16
TR199903191T2 (xx) 2000-09-21
CN1261287A (zh) 2000-07-26
CZ289570B6 (cs) 2002-02-13
NZ501066A (en) 2001-01-26
IL132918A (en) 2001-09-13
PL191295B1 (pl) 2006-04-28
CN1125653C (zh) 2003-10-29
TW406023B (en) 2000-09-21
IS2004B (is) 2005-04-15
EP1001813B1 (en) 2003-05-02
CA2295035C (en) 2005-04-19
EP1001813B8 (en) 2014-02-12
IS5248A (is) 1999-11-15
HU228338B1 (en) 2013-03-28
EG23910A (en) 2007-12-30
CZ409699A3 (cs) 2000-02-16
ME00907B (me) 2007-08-03
GB9713149D0 (en) 1997-08-27
SK159399A3 (en) 2000-06-12
PL337692A1 (en) 2000-08-28
BR9809468A (pt) 2000-06-20
ID22939A (id) 1999-12-16
IL132918A0 (en) 2001-03-19
ES2195355T3 (es) 2003-12-01
BG64584B1 (bg) 2005-08-31
PE84899A1 (es) 1999-09-17
JP2000513029A (ja) 2000-10-03
MA26508A1 (fr) 2004-12-20
EA001924B1 (ru) 2001-10-22
AR015900A1 (es) 2001-05-30
RS49633B (sr) 2007-08-03
AU724799B2 (en) 2000-09-28
SI1001813T1 (en) 2004-02-29
AP9801268A0 (en) 1998-06-30
US6632803B1 (en) 2003-10-14
BRPI9809468B8 (pt) 2022-01-18
HK1027966A1 (en) 2001-02-02
DK1001813T3 (da) 2003-07-28
ZA985364B (en) 1999-12-20
UY25055A1 (es) 2000-12-29
DE69814091T2 (de) 2004-01-22
YU68199A (sh) 2002-06-19
PA8453201A1 (es) 2000-05-24
OA11232A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
TR199901077A2 (en) �spen�iyari form�lasyonlar.
MX9300662A (es) Derivados fosfonooxi y carbonato de taxol
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
MX9202166A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion su empleo y agentes que los con tienen en calidad de anticoagulantes.
UY24386A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
ES2175127T3 (es) Derivados de la quinazolina y su uso.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
AR005999A1 (es) Nuevos derivados de eritromicina, su procedimiento de preparacion, composiciones farmaceuticas y medicamentos
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ES2191241T3 (es) Preparaciones farmaceuticas por via oral que comprenden s-(3-hidroxipropil)-l-cisteina.
ES2164168T3 (es) Antagonistas de receptores de fibrinogeno que tienen residuos de beta-aminoacido sustituidos y composiciones farmaceuticas que comprenden los mismos.
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol